Apr 2022 $40 M No. 3 $10 to $50 million 9
Atlas Therapeutics Corp: Raise no. 3, Apr 2022 × Investors in this round 9 investors had bought by the notice of Apr 19, 2022: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $40 M of $79 M offered; $39 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $2,000,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Mark Edward Doerr · Executive Officer, Director Ramona Edward Seabaugh · Executive Officer Gerald C. Gradwell · Director Glen R. Stettin · Director Laurie R. McGraw · Director Michael R. Kramer · Director Paul D. Johnson · Director Robert C. Faulkner · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Cowen and Company, LLC (CRD 7616) · New York, New York Sold in CA, IL, NY, and outside the US Signed by Ramona Seabaugh, Chief Financial Officer. Newest notice filed Apr 19, 2022. Read the notice at the SEC .
equity, options SEC Jan 2014 $5 M No. 2 $2 to $10 million 32
Atlas Therapeutics Corp: Raise no. 2, Jan 2014 × Investors in this round 32 investors had bought by the notice of Feb 6, 2014: 32 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $6 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue $1 million to $5 million
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Carl J. DeFreitas · Executive Officer, Director Peter Levy · Executive Officer Buzz J. Aldrin · Director Louis J. Aronne · Director Peter J. Diamandis · Director Robert J. Hariri · Director Sapna J. Srivastava · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Brean Capital, LLC (CRD 23723) · New York, New York Sold in CT, MA, MD, NJ, NV, NY, TX Remarks in the notice On fees: “The placement agent received shares of the Issuer's common stock and no cash commissions.”Signed by Peter Levy, President. Newest notice filed Feb 6, 2014. Read the notice at the SEC .
equity, options SEC Jul 2012 $6 M No. 1 $2 to $10 million 55
Atlas Therapeutics Corp: Raise no. 1, Jul 2012 × Investors in this round 55 investors had bought by the notice of Jul 11, 2012: 55 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken $10,000
What was sold equity
Meant to last a year or less
Issuer's revenue Up to $1 million
Sales commissions $178,800
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Peter Levy · Executive Officer Buzz J. Aldrin · Director Louis J. Aronne · Director Peter J. Diamandis · Director Robert J. Hariri · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Chardan Capital Markets, LLC (CRD 120128) · New York, New York Sold in IL, MD, NY, PA Remarks in the notice On fees: “The placement agent received a commission on the aggregate purchase price paid by investors it introduced to the issuer.”Signed by Peter Levy, Chief Operating Officer. Newest notice filed Jul 11, 2012. Read the notice at the SEC .
equity SEC Feb 2011 $1 M Issued in a merger or acquisition Under $2 million 4
Atlas Therapeutics Corp: Private sale, Feb 2011 × Investors in this round 4 investors had bought by the notice of Mar 8, 2011: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $3 M offered; $1 M still to sell
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue No revenue
Sales commissions none
Finders' fees none
Paid to its own people $450,000 (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice Carlon Colker, MD, FACN · Executive Officer J.B. Bernstein · Executive Officer, Director Georgette Mathers · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the use of proceeds: “Consideration for assets purchased from seller who simultaneously became an executive officer of the Issuer.”On a merger: “Please see the Issuer's Form 8-K filed with the SEC on EDGAR on March 3, 2011.”Signed by J.B. Bernstein, Chief Executive Officer. Newest notice filed Mar 8, 2011. Read the notice at the SEC .
equity, options SEC